Index

Age-related macular degeneration (AMD), treatments for, 123–124. *See also* Neovascular AMD
  combination therapy, 126
  continuation therapy, 125–126
  cost considerations, 127
  induction/maintenance therapy, 124–125
  non-AMD disease targets, 126–127
Allergic conjunctivitis, and Elestat
  description of, 87–88
  efficacy of Elestat, 90–92
  ocular surface considerations, 94–97
  pathophysiology, 88
  properties of epinastine, 88–89
  safety of, 92–94
Anti-VEGF therapy, with Macugen, 141–151
  benefits of continuing Macugen for a second year, 145
  investigational applications, 151
  Macugen efficacy in treatment of early AMD, 145–147
  other ocular neovascular diseases treatment by, 148–151
  pathogenesis of ocular neovascular disease, 142–143
  safety and tolerability of Macugen, 147–148
  V.I.S.I.O.N Trials established the efficacy of Macugen for AMD, 143–145
Atopic keratoconjunctivitis and cyclosporine, 112

Bacterial conjunctivitis and Zymar, 79
Bacterial keratitis, and Zymar, 79
Benzalkonium chloride (BAK) and potency of fourth-generation fluoroquinolones, 68–69
Bromfenac ophthalmic solution 0.09%. *See* Xibrom

Cataract surgery, NSAIDs for treating inflammation and pain after, 7–10
  bromfenac ophthalmic solution 0.09% for, 27–31
Combination therapy and AMD, 126
Contact lens intolerance and cyclosporine, 113–114
Continuation therapy and AMD, 125–126
Corneal allograft rejection, and cyclosporine, 113
COX-2 enzyme and Xibrom, 23–24
Cyclosporine A, for ocular surface disease treatment
  historical perspective, 105–106
  indications, approved, 108–112
  off-label therapy by, 112–117
  pharmacology and mechanism of action, 106–108
Cyclosporine emulsion therapy for dry eye, 101–102. *See also* Cyclosporine A, for ocular surface disease treatment
Cystoid macular edema (CME), NSAIDs for prevention and treatment of, 9–10
Cytotoxicity and Zymar, 77–78

Diabetic macular edema (DME), and Macugen, 148–149
Diabetic retinal neovascularization, and Macugen, 149–150
Dry eye and cyclosporine therapy, 101–102

Early AMD, Macugen efficacy in treatment of, 145–147
Elestat, for allergic conjunctivitis
  efficacy of, 90–92
  ocular surface considerations, 94–97
  pathophysiology of allergic conjunctivitis, 88
  properties of epinastine, 88–89
  safety of, 92–94

Endophthalmitis, and Zymar, 79–81
Epinastine, for ocular allergic disease, 85–86
Epinastine HCl 0.05% ophthalmic solution. *See* Elestat
Eyelid margin disease and cyclosporine
  meibomian gland dysfunction, 114
  ocular rosacea, 114–115

Fluoroquinolones. *See* Ophthalmic fluoroquinolones
Fourth-generation fluoroquinolone. *See* Vigamox; Zymar
Fungal keratitis, and cyclosporine, 116–117

Gatifloxacin ophthalmic solution 0.3%. *See* Zymar
Graft *versus* host disease (GVHD), and cyclosporine, 116

Herpes simplex keratitis, and cyclosporine, 117
Human tear concentration study and Iquix, 57–58

Induction/maintenance therapy and AMD, 124–125
Iquix, Vigamox, and, Zymar for the management of ocular infectious disease, integration of, 41–43
Iquix (levofloxacin 1.5%), research review and update
  antimicrobial resistance data, 47–48
  comparative study of penetration of gatifloxacin, moxifloxacin, and, 50–52
  concentration, solubility, and penetration, 48–49
  formulation of, 49–50
  human tear concentration study, 57–58
  indications for, 58
  safety and efficacy study of, 52–57

Kill kinetics, of topically administered fluoroquinolones, 67–68

Laser-assisted in situ keratomileusis (LASIK)-associated dry eye, and cyclosporine, 115–116
Leber congenital amaurosis, 2
Levofloxacin ophthalmic solution. *See* Iquix

Macugen, for other ocular neovascular diseases treatment
  diabetic macular edema (DME), 148–149
  diabetic retinal neovascularization, 149–150
  investigational applications of, 151
  macular edema secondary to CRVO, 150–151
Macugen, for AMD treatment, 123–124
  combination therapy, 126
  continuation therapy, 125–126
  induction/maintenance therapy, 124–125
Macugen, for neovascular AMD treatment, 141
  benefits of continuing Macugen for a second year, 145
  investigational applications, 151
  Macugen efficacy in treatment of early AMD, 145–147
  other ocular neovascular diseases treatment by, 148–151
  pathogenesis of ocular neovascular disease, 142–143
  safety and tolerability of Macugen, 147–148
  V.I.S.I.O.N Trials established the efficacy of Macugen for AMD, 143–145
Macular edema secondary to CRVO, and Macugen, 150–151
Meibomian gland dysfunction and cyclosporine, 114
Moxifloxacin ophthalmic solution 0.5%. *See* Vigamox

Neovascular AMD, ranibizumab treatment for, 131–132. *See also* Ocular neovascular disease treatment, with Macugen
  clinical trials with other dosing strategies, 137–138
  drug development, 133–134
  future directions of, 138
  phase 3 clinical trials, 134–137
  preclinical data, 134
  VEGF-targeted therapy rationale, 132–133
Nepafenac, 8–9
  clinical data, 17–19

pharmacology, 13
preclinical data, 14–17
Nonsteroidal anti-inflammatory drugs (NSAIDs), pharmacologic and pathophysiologic rationale for using. *See also* Ophthalmic NSAIDs
for cystoid macular edema (CME) prevention and treatment, 9–10
in ocular inflammation and pain, 7–8

Ocular allergic disease, and epinastine, 85–86. *See also* Allergic conjunctivitis
Ocular allergic disease, cyclosporine therapy for
atopic keratoconjunctivitis, 114
corneal allograft rejection, 113
vernal keratoconjunctivitis, 112–113
Ocular infectious diseases
integration of Iquix, Vigamox, and Zymar for, 41–43
Iquix for, 47–59
Vigamox for, 61–70
Zymar for, 73–81
Ocular infectious diseases, cyclosporine therapy for
fungal keratitis, 116–117
herpes simplex keratitis, 117
Ocular inflammatory disease and ocular surgery, NSAIDs for
cystoid macular edema (CME) prevention and treatment, 9–10
in ocular inflammation and pain, 7–8
Ocular neovascular disease treatment, with Macugen, 141
benefits of continuing Macugen for a second year, 145
diabetic macular edema (DME) treatment, 148–149
diabetic retinal neovascularization treatment, 149–150
investigational applications of, 151
Macugen efficacy in treatment of early AMD, 145–147
macular edema secondary to CRVO treatment, 150–151
pathogenesis of ocular neovascular disease, 142–143
safety and tolerability of Macugen, 147–148
V.I.S.I.O.N Trials established the efficacy of Macugen for AMD, 143–145
Ocular rosacea, and cyclosporine, 114–115
Ocular safety and bromfenac ophthalmic solution, 33–35
Ocular surface disease, and cyclosporine emulsion therapy for
atopic keratoconjunctivitis, 112
contact lens intolerance due to tearfilm instability, 113–114
corneal allograft rejection, 113
fungal keratitis, 116–117
graft *versus* host disease (GVHD), 116
herpes simplex keratitis, 117
historical perspective, 105–106
indications, approved, 108–112
LASIK-associated dry eye treatment, 115–116
meibomian gland dysfunction, 114
ocular rosacea, 114–115
pharmacology and mechanism of action, 106–108
vernal keratoconjunctivitis, 112–113
Ocular surgery. *See* Cataract surgery, NSAIDs for treating inflammation and pain after
Ocular therapeutics
recent advances in, 1–5
Ophthalmic fluoroquinolones. *See also* Iquix; Vigamox; Zymar
antimicrobial efficacy of, 75–77
benzalkonium chloride (BAK) and potency of fourth-generation, 68–69
kill kinetics of topically administered, 67–68
Ophthalmic NSAIDs
clinical applications of, 31–33
nepafenac, 8–9, 13–19
Xibrom, 21

Pegaptanib sodium. *See* Macugen
Pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery
for cystoid macular edema (CME) prevention and treatment, 9–10
in ocular inflammation and pain, 7–8

Ranibizumab, for treatment of ocular diseases
clinical trials with other dosing strategies, 137–138
drug development, 133–134
future directions of, 138
phase 3 clinical trials, 134–137
preclinical data, 134
VEGF-targeted therapy rationale for, 132–133
Restasis. *See* Cyclosporine emulsion therapy for dry eye

Systemic safety and bromfenac ophthalmic solution, 35

Topical cyclosporine. *See* Cyclosporine A, for ocular surface disease treatment
Tracking Resistance in the United States Today (TRUST) study and Iquix, 47–48

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N) Trials established the efficacy of Macugen for AMD, 143–145
VEGF-targeted therapy, with ranibizumab, 132–133
Vernal keratoconjunctivitis and cyclosporine, 112–113
Vigamox, Iquix, and Zymar for the management of ocular infectious disease, integration of, 41–43
Vigamox (moxifloxacin), evidence-based review of, 61–62
benzalkonium chloride and potency of fourth-generation fluoroquinolones, 68–69
kill kinetics of topically administered fluoroquinolones, 67–68
penetration of, 62–65
potency of, 65–67
safety of, 69–70

Wound healing, effects on, and Zymar, 77–78

Xibrom, clinical and postapproval experience with, 21
chemical structure of, 22
clinical applications of, 31–33
efficacy in treating inflammation and pain following cataract surgery, 27–31
importance of convenience and comfort to compliance, 35–37
NSAID mechanism of action, 22
ocular safety, 33–35
preclinical studies of, 22–27
systemic safety of, 35
Xibrom, preclinical studies of, 22
penetration into ocular tissue, 24–27
potency against the COX-2 enzyme, 23–24

Zymar
antimicrobial efficacy, 75–77
cytotoxicity and effects on wound healing, 77–78
molecular properties, 73–75
safety and tolerability, 79
tissue penetration, 77
Vigamox, Iquix, and, for the management of ocular infectious disease, integration of, 41–43
Zymar, therapeutic uses of
bacterial conjunctivitis, 79
bacterial keratitis, 79
endophthalmitis prevention, 79–81